Overview

Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS)

Status:
Active, not recruiting

Trial end date:
2021-11-15

Target enrollment:

Participant gender:

Summary

The main purpose of the study is to assess the health-related quality of life (HRQoL) through the Multiple Sclerosis Quality of Life-54 Questionnaire (MSQoL-54) scale in highly-active relapsing multiple sclerosis (RMS) subjects treated with Mavenclad® for 2 years (24 months).

Phase:

Phase 4

Details

Lead Sponsor:

Merck KGaA, Darmstadt, Germany

Treatments:

Cladribine